# **CRF Problem Report**

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: 09/ Date Processed by STIC:

STIC Contact: Mark Spencer, 703-308-4212

## Nature of Problem:

The CRF (was):

Filing Date:

(circle one) Damaged or Unreadable (for Unreadable, see attached) Blank (no files on CRF) (see attached)

Empty file (filename present, but no bytes in file) (see attached)

Virus-infected. Virus name: \_\_\_\_\_ The STIC will not process the CRF.

Not saved in ASCII text

Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should only be the Sequence Listing.

Did not contain a Sequence Listing. (see attached sample)

Other:

### PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS. **SEE BELOW FOR ADDRESS:**

http:/www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a>>, EFS Submission User Manual - ePAVE)
- 2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
- 3. Hand Carry directly to:
  - U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
  - U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
- 4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office. Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

BIOTECHNOLOGY

TECH CENTER 1600/2900



Attorney's Docket No.: <u>H00666.70000.US</u>

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Tanida et al.

Serial No.

09/700,817

Filing Date

May 17, 1999

For

SOLID PREPARATIONS FOR ORAL ADMINISTRATION

OF GENE-RELATED DRUGS

Examiner

R. Schnizer

Art Unit

1635

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 8th day of October, 2002.

Monica E. Zombori

Commissioner for Patents Washington, DC 20231

#### STATEMENT UNDER 37 C.F.R. §1.821(f)

Sir:

This statement is made pursuant to 37 CFR 1.821(f). Applicant encloses herewith an original written copy of the Sequence Listing and a computer readable diskette. Applicant's attorney states that the information recorded in the computer readable form is identical to the written Sequence Listing and that the Sequence Listing contains no new matter.

Respectfully submitted,

John R. Van Amsterdam, Reg No. 40,212

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue Boston, MA 02210

Telephone (617) 720-3500

Attorney's Docket No. H00666.70000.US

Dated: October 8, 2002

X10/26/02

Application No.: 09/700,817

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING **NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the
- content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: The oligonucleotide sequence on page 12 is greater than 10 bases in length but is not identified by a SEQ ID NO:1. Correction is required. A Sequence Listing and CRF must be submitted as discussed below.

#### Applicant Must Provide:

A <u>new</u> computer readable form (CRF) copy of the "Sequence Listing".

A new paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact: RECEIVED

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software......703-306-2600

OCT 1 8 2002

**TECH CENTER 1600/2900** 

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY